(Bloomberg) -- Fresenius SE has agreed to sell a controlling stake in the rehabilitation business of its Vamed unit to French private equity firm PAI Partners as the German healthcare company further trims its portfolio.Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesBiden Calls Ally Japan ‘Xenophobic’ Along With China, RussiaIn Jamie Dimo
Key Insights Fresenius SE KGaA's significant retail investors ownership suggests that the key decisions are influenced...
Today we're going to take a look at the well-established Fresenius SE & Co. KGaA ( ETR:FRE ). The company's stock saw...